@article{10902/18726,
year = {2019},
url = {http://hdl.handle.net/10902/18726},
abstract = {Introduction: The ROS1 gene rearrangement has become an important biomarker in NSCLC. The College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology testing guidelines support the use of ROS1 immunohistochemistry (IHC) as a screening test, followed by confirmation with fluorescence in situ hybridization (FISH) or a molecular test in all positive results. We have evaluated a novel anti-ROS1 IHC antibody (SP384) in a large multicenter series to obtain real-world data.

Methods: A total of 43 ROS1 FISH-positive and 193 ROS1 FISH-negative NSCLC samples were studied. All specimens were screened by using two antibodies (clone D4D6 from Cell Signaling Technology and clone SP384 from Ventana Medical Systems), and the different interpretation criteria were compared with break-apart FISH (Vysis). FISH-positive samples were also analyzed with next-generation sequencing (Oncomine Dx Target Test Panel, Thermo Fisher Scientific).

Results: An H-score of 150 or higher or the presence of at least 70% of tumor cells with an intensity of staining of 2+ or higher by the SP384 clone was the optimal cutoff value (both with 93% sensitivity and 100% specificity). The D4D6 clone showed similar results, with an H-score of at least 100 (91% sensitivity and 100% specificity). ROS1 expression in normal lung was more frequent with use of the SP384 clone (p < 0.0001). The ezrin gene (EZR)-ROS1 variant was associated with membranous staining and an isolated green signal FISH pattern (p = 0.001 and p = 0.017, respectively).

Conclusions: The new SP384 ROS1 IHC clone showed excellent sensitivity without compromising specificity, so it is another excellent analytical option for the proposed testing algorithm.},
organization = {Funding for this study was provided by Instituto de Salud Carlos III (ISCIII) (Fondos FEDER and Plan Estatal de IþDþI 2013-2016 [PI14-01176 and PI17-01001], 2018-2021 [PI18/00382], and PT17/0015/0006]) and the iLUNG Program (B2017/BMD-3884) from the Comunidad de Madrid. Ventana Medical Systems provided the clone SP384 free of charge. Thermo Fisher Scientific provided the Oncomine Dx Target Test panel free of charge. Dr. F. Lopez-Rios thanks T. Crean for his constant support.},
publisher = {Elsevier},
publisher = {J Thorac Oncol
. 2019 Dec;14(12):2120-2132},
title = {Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients With Non-Small Cell Lung Carcinoma: The ROSING Study},
author = {Conde, Esther and Hernández, Susana and Martinez, Rebeca and Angulo, Barbara and Castro, Javier De and Collazo-Lorduy, Ana and Jimenez, Beatriz and Muriel, Alfonso and Mate, Jose Luis and Moran, Teresa and Aranda, Ignacio and Massuti, Bartomeu and Rojo, Federico and Domine, Manuel and Sansano, Irene and Garcia, Felip and Felip, Enriqueta and Mancheño, Nuria and Juan, Oscar and Gómez Román, José Javier},
}